Larimar Therapeutics (LRMR) Cash & Current Investments (2016 - 2020)
Historic Cash & Current Investments for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $102.3 million.
- Larimar Therapeutics' Cash & Current Investments rose 2475.79% to $102.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $102.3 million, marking a year-over-year increase of 2475.79%. This contributed to the annual value of $44.1 million for FY2019, which is 6268.27% down from last year.
- Larimar Therapeutics' Cash & Current Investments amounted to $102.3 million in Q3 2020, which was up 2475.79% from $113.7 million recorded in Q2 2020.
- Larimar Therapeutics' Cash & Current Investments' 5-year high stood at $166.2 million during Q1 2016, with a 5-year trough of $44.1 million in Q4 2019.
- Moreover, its 5-year median value for Cash & Current Investments was $104.7 million (2019), whereas its average is $106.1 million.
- Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 8004.38% in 2016, then plummeted by 6268.27% in 2019.
- Over the past 5 years, Larimar Therapeutics' Cash & Current Investments (Quarter) stood at $129.2 million in 2016, then fell by 21.01% to $102.1 million in 2017, then increased by 15.69% to $118.1 million in 2018, then tumbled by 62.68% to $44.1 million in 2019, then surged by 132.21% to $102.3 million in 2020.
- Its Cash & Current Investments stands at $102.3 million for Q3 2020, versus $113.7 million for Q2 2020 and $63.9 million for Q1 2020.